<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Psychosocial interventions for schizophrenia in children and adolescents</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Psychosocial interventions for schizophrenia in children and adolescents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Psychosocial interventions for schizophrenia in children and adolescents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Brian Skehan, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Yael Dvir, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Brent, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen Marder, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Friedman, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 17, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3346353019"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Schizophrenia in children and adolescents is a syndrome consisting of positive and negative symptoms of psychosis that impact development and cognitive functioning. The etiology of this syndrome is poorly understood, but early diagnosis and treatment are critical to limit the morbidity of the disorder.</p><p>Childhood-onset schizophrenia usually represents a more severe form of the disorder with more prominent prepsychotic developmental disorders, structural brain abnormalities, and genetic risk factors [<a href="#rid1">1-4</a>].</p><p>This topic reviews psychosocial interventions for schizophrenia in children and adolescents. The epidemiology, pathogenesis, clinical manifestations, course, assessment, diagnosis, and treatment of schizophrenia in children are reviewed separately. The epidemiology, pathogenesis, clinical manifestations, course, assessment, diagnosis, and treatment of schizophrenia in adults (including long-acting injectable antipsychotics, <a class="drug drug_pediatric" data-topicid="12995" href="/z/d/drug information/12995.html" rel="external">clozapine</a>, medication to treat side effects, and the evaluation and management of treatment-resistant schizophrenia) are also reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14365.html" rel="external">"Schizophrenia in children and adolescents: Epidemiology, clinical features, assessment, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6962.html" rel="external">"Schizophrenia in adults: Clinical features, assessment, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14804.html" rel="external">"Schizophrenia in adults: Epidemiology and pathogenesis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15250.html" rel="external">"Schizophrenia in adults: Pharmacotherapy with long-acting injectable antipsychotic medication"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15774.html" rel="external">"Schizophrenia in adults: Psychosocial management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14808.html" rel="external">"Evaluation and management of treatment-resistant schizophrenia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14772.html" rel="external">"Schizophrenia in adults: Guidelines for prescribing clozapine"</a>.)</p><p></p><p class="headingAnchor" id="H1430844239"><span class="h1">PSYCHOSOCIAL INTERVENTIONS</span><span class="headingEndMark"> — </span>Psychosocial interventions for children/adolescents with schizophrenia, in our clinical experience, are important adjuncts to treatment with antipsychotic medication.</p><p>The availability of psychosocial treatments for children with schizophrenia varies widely internationally. In the United States, they are more likely to be available in major metropolitan areas with large academic medical centers rather than in smaller cities or more rural areas. Psychosocial treatment programs may be more likely to incorporate principles and techniques from modalities we describe rather than to deliver a series of specific, discrete interventions.</p><p>There have been few clinical trials of these interventions in youth; however, they are widely used clinically. Most were originally developed for adults; use in children requires customization to fit the patient’s age, development, social setting, family, and risk factors.</p><p class="headingAnchor" id="H2433463170"><span class="h2">Psychoeducation</span><span class="headingEndMark"> — </span>Psychoeducation, best provided early in treatment and frequently reviewed, provides children and their parents/support persons information about the illness, medications, and other interventions. It is highly useful to have family members integrated into the treatment team and educated in order to support the youth effectively and to enhance compliance.</p><p>There are no clinical trials evaluating the efficacy of psychoeducational interventions for children/adolescents with schizophrenia and their families; however, in our clinical experience, developmentally appropriate psychoeducation is a critical component of care. Psychoeducation and family interventions for schizophrenia in adults are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/15774.html" rel="external">"Schizophrenia in adults: Psychosocial management", section on 'Family-based Interventions'</a>.)</p><p class="headingAnchor" id="H2164423916"><span class="h2">Individual and family therapy</span><span class="headingEndMark"> — </span>Individual and/or family therapy for children/adolescents with schizophrenia varies in content but typically includes some combination of education, support, and/or principles of problem solving therapy or cognitive-behavioral therapy (CBT).</p><p class="headingAnchor" id="H3040845874"><span class="h3">Cognitive-behavioral therapy</span><span class="headingEndMark"> — </span>CBT for children/adolescents with schizophrenia (and in some cases family members) consists of:</p><p class="bulletIndent1"><span class="glyph">●</span>Cognitive approaches to address maladaptive and delusional beliefs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Behavioral approaches, including social and vocational skills training. (See <a class="local">'Skills training'</a> below.)</p><p></p><p>Treatment goals of CBT include reducing the intensity of delusions and hallucinations (and related distress), improving social functioning, and promoting the active engagement of children and families in treatment.</p><p>Clinical trials have found mixed evidence for the efficacy of CBT in children/adolescents with schizophrenia<strong> </strong>[<a href="#rid5">5-7</a>]. As an example, a clinical trial randomly assigned 62 participants age 15 to 25 years with a first episode of psychosis to receive either CBT or a control condition [<a href="#rid6">6</a>]. After 14 weeks, both groups had reductions in positive and negative symptoms, but no difference was seen between them in symptomatic or functional improvement.</p><p>CBT is used in adult schizophrenia to treat patients with symptoms resistant to antipsychotic medication. In contrast, in our clinical experience, all children with schizophrenia could benefit from CBT.</p><p>CBT for schizophrenia in adults is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/15774.html" rel="external">"Schizophrenia in adults: Psychosocial management", section on 'Cognitive-behavioral therapy'</a>.)</p><p class="headingAnchor" id="H242461517"><span class="h2">Skills training</span><span class="headingEndMark"> — </span>Social and vocational skills training are important components of psychosocial treatment for children. Surveys of patients consistently show positive functional outcomes as being equally, if not more, important to the patients than remission of symptoms [<a href="#rid8">8</a>]. Social skills training is aimed at children with observed deficits such as problems with attention and working memory (eg, poor affect regulation). All adolescents should receive age-appropriate vocational skills training, which may also include help with placement and support during employment.</p><p>A clinical trial supports the use of vocational skills training in this population [<a href="#rid8">8</a>]. Forty-one patients in the United Kingdom ages 15 to 25 years with schizophrenia were randomly assigned to receive individual placement and support or a control condition; patients assigned to the active intervention had higher rates of employment, earnings, and duration of employment compared with control group [<a href="#rid9">9</a>].</p><p>Social skills training for adults with schizophrenia is described separately. (See  <a class="medical medical_review" href="/z/d/html/15774.html" rel="external">"Schizophrenia in adults: Psychosocial management", section on 'Social skills training'</a>.)</p><p class="headingAnchor" id="H3899147054"><span class="h2">Therapeutic schools</span><span class="headingEndMark"> — </span>Therapeutic schools are used to educate children who struggle accessing the curriculum in a typical school setting due to mental illness or other emotional, behavioral, or psychological conditions. These schools vary but may offer academic assistance, counseling, behavior modification, individual and group therapy, as well as developmentally appropriate skill building to support these youth. Children or adolescents with schizophrenia who are treatment-resistant or who have associated cognitive/emotional challenges can benefit from therapeutic schools.</p><p>There are no clinical trials of the efficacy of therapeutic schools in youth with schizophrenia.</p><p class="headingAnchor" id="H1134598262"><span class="h2">Cognitive enhancement/remediation</span><span class="headingEndMark"> — </span>All youth with schizophrenia should receive cognitive enhancement therapy (or the similar cognitive remediation), if available, which consist of:</p><p class="bulletIndent1"><span class="glyph">●</span>Computer-based exercises aimed at slowing deterioration in attention, memory, language, and executive functioning [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Social-cognitive group sessions for experiential learning and interpersonal interactions.</p><p></p><p>Clinical trials suggest that cognitive enhancement therapy or remediation may be superior to other psychotherapies:</p><p class="bulletIndent1"><span class="glyph">●</span>A two-year clinical trial randomly assigned 58 youth with early onset psychosis to receive either cognitive enhancement therapy or to enriched supportive therapy, finding that cognitive enhancement therapy led to superior results on social cognition, social adjustment, and symptomatology for cognition [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A three-month trial of cognitive remediation therapy in 40 adolescents with schizophrenia was found to be superior for cognitive flexibility (as evidenced by the Wisconsin Card Sort Test) in comparison to standard therapy [<a href="#rid12">12</a>].</p><p></p><p>Although the availability of cognitive enhancement therapy, like other psychosocial interventions for youth with schizophrenia, is limited geographically, their availability is expanding to include online resources that can be done by the youth at home, which may provide benefit. Standardized definitions of cognitive remediation/enhancement components have not been well defined; further study is needed.</p><p>Cognitive remediation for adults with schizophrenia is described separately. (See  <a class="medical medical_review" href="/z/d/html/15774.html" rel="external">"Schizophrenia in adults: Psychosocial management", section on 'Cognitive remediation'</a>.)</p><p class="headingAnchor" id="H3476926753"><span class="h1">FOR HIGH CLINICAL RISK</span><span class="headingEndMark"> — </span>Psychosocial interventions paired with pharmacologic management have been tested for their ability to prevent or delay the onset of psychotic disorders in children at high (or “ultra-high”) clinical risk of developing a psychotic disorder. The criteria for these high-risk states vary, ranging from prodromal symptoms (ie, disorganized or unusual thought content such as paranoia or suspiciousness, disorganized behavior) to the presence of psychotic symptoms below the threshold of a psychotic disorder.</p><p>A clinical trial randomly assigned 51 youth/young adults (age range 14 to 30) at “ultra-high” risk for psychosis to receive either cognitive-behavioral therapy (CBT) or supportive therapy [<a href="#rid13">13</a>]. No differences were found between groups at 6- or 12-month follow-up, though both groups showed improvement from baseline in attenuated positive symptoms, anxiety, and depression.</p><p>The findings are consistent with our clinical experience in suggesting that all youth with these high-risk symptoms would benefit from supportive therapy or CBT as well as close clinical monitoring for conversion to psychosis.</p><p class="headingAnchor" id="H158579615"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117525.html" rel="external">"Society guideline links: Psychotic disorders"</a>.)</p><p></p><p class="headingAnchor" id="H944502899"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction</strong> – Schizophrenia in children and adolescents is a syndrome consisting of positive and negative symptoms of psychosis that impact development and cognitive functioning. The etiology of this syndrome is poorly understood, but early diagnosis and treatment are critical to limit the morbidity of the disorder. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1">Antipsychotic medication is the cornerstone of treatment for schizophrenia in youth, augmented by psychosocial treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psychosocial interventions </strong>– Psychosocial interventions are important adjuncts to antipsychotic treatment for children/adolescents with schizophrenia, but have received little study in clinical trials. (See <a class="local">'Psychosocial interventions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Psychoeducation </strong>– Psychoeducation gives children and their parents/support persons information about the illness, medications, and other interventions. (See <a class="local">'Psychoeducation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Individual and family therapy</strong> – Individual and/or family therapy for children/adolescents with schizophrenia varies in content but typically includes some combination of education, support, and/or principles of problem solving therapy or cognitive-behavioral therapy. (See <a class="local">'Individual and family therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Skills training</strong> – Age-appropriate training in vocational skills and social skills are important components of psychosocial treatment for children. These interventions aim to prevent deterioration in vocational and interpersonal functioning. (See <a class="local">'Skills training'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Therapeutic schools</strong> – Therapeutic schools are used to educate children who struggle accessing the curriculum in a typical school setting due to mental illness or other emotional, behavioral, or psychological conditions. (See <a class="local">'Therapeutic schools'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cognitive enhancement and remediation</strong> – Cognitive remediation therapy consists of computer-based exercises aimed at slowing deterioration in attention, memory, language, and executive functioning. Additionally social-cognitive group sessions offer experiential learning and interpersonal interactions. (See <a class="local">'Cognitive enhancement/remediation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High clinical risk of psychosis</strong> – Psychosocial interventions paired with pharmacologic management have been tested for their ability to prevent or delay the onset of psychotic disorders in children at high (or “ultra-high”) clinical risk of developing a psychotic disorder. (See <a class="local">'For high clinical risk'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Childs B, Scriver CR. Age at onset and causes of disease. Perspect Biol Med 1986; 29:437.</a></li><li><a class="nounderline abstract_t">Rapoport JL, Gogtay N. Childhood onset schizophrenia: support for a progressive neurodevelopmental disorder. Int J Dev Neurosci 2011; 29:251.</a></li><li><a class="nounderline abstract_t">Nicolson R, Malaspina D, Giedd JN, et al. Obstetrical complications and childhood-onset schizophrenia. Am J Psychiatry 1999; 156:1650.</a></li><li><a class="nounderline abstract_t">Nicolson R, Giedd JN, Lenane M, et al. Clinical and neurobiological correlates of cytogenetic abnormalities in childhood-onset schizophrenia. Am J Psychiatry 1999; 156:1575.</a></li><li><a class="nounderline abstract_t">Gleeson JF, Cotton SM, Alvarez-Jimenez M, et al. A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients. J Clin Psychiatry 2009; 70:477.</a></li><li><a class="nounderline abstract_t">Jackson HJ, McGorry PD, Killackey E, et al. Acute-phase and 1-year follow-up results of a randomized controlled trial of CBT versus Befriending for first-episode psychosis: the ACE project. Psychol Med 2008; 38:725.</a></li><li><a class="nounderline abstract_t">Haddock G, Lewis S, Bentall R, et al. Influence of age on outcome of psychological treatments in first-episode psychosis. Br J Psychiatry 2006; 188:250.</a></li><li><a class="nounderline abstract_t">Killackey E, Alvarez-Jimenez M, Allott K, et al. Community rehabilitation and psychosocial interventions for psychotic disorders in youth. Child Adolesc Psychiatr Clin N Am 2013; 22:745.</a></li><li><a class="nounderline abstract_t">Killackey E, Jackson HJ, McGorry PD. Vocational intervention in first-episode psychosis: individual placement and support v. treatment as usual. Br J Psychiatry 2008; 193:114.</a></li><li><a class="nounderline abstract_t">Prikken M, Konings MJ, Lei WU, et al. The efficacy of computerized cognitive drill and practice training for patients with a schizophrenia-spectrum disorder: A meta-analysis. Schizophr Res 2019; 204:368.</a></li><li><a class="nounderline abstract_t">Eack SM, Greenwald DP, Hogarty SS, et al. Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial. Psychiatr Serv 2009; 60:1468.</a></li><li><a class="nounderline abstract_t">Wykes T, Newton E, Landau S, et al. Cognitive remediation therapy (CRT) for young early onset patients with schizophrenia: an exploratory randomized controlled trial. Schizophr Res 2007; 94:221.</a></li><li><a class="nounderline abstract_t">Addington J, Epstein I, Liu L, et al. A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res 2011; 125:54.</a></li></ol></div><div id="topicVersionRevision">Topic 112632 Version 10.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3714435" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Age at onset and causes of disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20955775" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Childhood onset schizophrenia: support for a progressive neurodevelopmental disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10518182" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Obstetrical complications and childhood-onset schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10518169" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical and neurobiological correlates of cytogenetic abnormalities in childhood-onset schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19323964" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18005494" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Acute-phase and 1-year follow-up results of a randomized controlled trial of CBT versus Befriending for first-episode psychosis: the ACE project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16507967" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Influence of age on outcome of psychological treatments in first-episode psychosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24012084" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Community rehabilitation and psychosocial interventions for psychotic disorders in youth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18669993" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Vocational intervention in first-episode psychosis: individual placement and support v. treatment as usual.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30097278" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The efficacy of computerized cognitive drill and practice training for patients with a schizophrenia-spectrum disorder: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19880464" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17524620" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cognitive remediation therapy (CRT) for young early onset patients with schizophrenia: an exploratory randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21074974" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
